Novel Hormone(新荷尔蒙)研究综述
Novel Hormone 新荷尔蒙 - Irisin, a novel hormone like polypeptide, is cleaved and secreted by an unknown protease from a membrane-spanning protein, FNDC5 (fibronectin type III domain-containing protein 5). [1] Irisin is a novel hormone that provides a possible solution for the treatment of metabolic disorders. [2] Irisin is a novel hormone‐like myokine that plays an important role in central nervous system (CNS) diseases, such as cerebral ischaemia and Alzheimer’s disease. [3] A novel hormone-sensitive lipase (HSL) family esterase, Est19, from the Antarctic bacterium Pseudomonas sp. [4] This report examines translational research on novel hormones, the natriuretic peptide family and leptin, which have achieved clinical applications or for which studies are still ongoing, and also emphasizes the lessons that translational science has learned from more than 30 years’ experience in translational research. [5]鸢尾素是一种新型激素样多肽，由一种未知蛋白酶从跨膜蛋白 FNDC5（含纤连蛋白 III 型结构域的蛋白 5）中切割和分泌。 [1] 鸢尾素是一种新型激素，可为治疗代谢紊乱提供可能的解决方案。 [2] 鸢尾素是一种新型激素样肌细胞因子，在脑缺血和阿尔茨海默病等中枢神经系统 (CNS) 疾病中起重要作用。 [3] 一种来自南极细菌假单胞菌的新型激素敏感性脂肪酶 (HSL) 家族酯酶 Est19。 [4] 本报告检视了关于新型激素、利钠肽家族和瘦素的转化研究，这些研究已经实现了临床应用或仍在进行中，并强调了转化科学从 30 多年的转化研究经验中吸取的教训。 [5]
white adipose tissue 白色脂肪组织
Background: Adiponectin (APN) is a novel hormone produced mainly by white adipose tissue that contribute to various physiological functions. [1]背景：脂联素（APN）是一种新型激素，主要由白色脂肪组织产生，有助于各种生理功能。 [1]
novel hormone therapy 新型激素疗法
Among evaluable PCa pts in the CGDB, (67 MYCamp and 658 MYCwt) MYCamp did not significantly impact treatment decisions, with the majority receiving novel hormone therapies (35. [1] Median prior lines of CRPC therapies was 2 (1-5), including 3 (25%) who had received prior chemotherapy and 100% a prior novel hormone therapy. [2] Safety/antitumor activity of PF-06753512 (PrCa VBIR) was evaluated in a phase I, dose-escalation and expansion study in patients (pts) with BCR prior to ADT and in pts with mCRPC either prior to or after failure of novel hormone therapy. [3] The treatment of de novo, synchronous castration-sensitive metastatic prostate cancer has undergone a revolution with the advent of novel hormone therapies and life-prolonging chemotherapy for use in combination with androgen-deprivation therapy. [4]在 CGDB 中可评估的 PCa 患者中，（67 个 MYCamp 和 658 个 MYCwt）MYCamp 对治疗决策没有显着影响，大多数人接受了新的激素疗法（35. [1] 先前 CRPC 治疗线的中位数为 2 (1-5)，包括 3 (25%) 曾接受过先前的化疗和 100% 的先前新激素治疗。 [2] PF-06753512 (PrCa VBIR) 的安全性/抗肿瘤活性在一项 I 期、剂量递增和扩展研究中对 ADT 之前的 BCR 患者（pts）和新型激素治疗失败之前或之后的 mCRPC 患者进行了评估. [3] 随着新型激素疗法和与雄激素剥夺疗法联合使用的延长生命的化学疗法的出现，从头、同步去势敏感性转移性前列腺癌的治疗经历了一场革命。 [4]